Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Date publication

janvier 2013

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis

Tous les auteurs :
Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23935912

Résumé

Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the French National Cancer Institute (INCa) has set up a national network of 28 regional molecular genetics centers. Concurrently, a nationwide external quality assessment for KRAS testing (MOKAECM) was granted to analyze reproducibility and costs.

Mots clés

Antibodies, Monoclonal, therapeutic use, Biopsy, Cell Line, Tumor, Colorectal Neoplasms, diagnosis, Fixatives, France, Genetic Testing, economics, Humans, Neoplasm Metastasis, Proto-Oncogene Proteins, analysis, Proto-Oncogene Proteins p21(ras), Receptor, Epidermal Growth Factor, antagonists & inhibitors, Reproducibility of Results, Sensitivity and Specificity, Sequence Analysis, DNA, economics, Tissue Embedding, ras Proteins, analysis

Référence

PLoS ONE. 2013 ;8(7):e68945